Figure 5

Hsa_circ_0081065 exacerbates HIF-1α nuclear translocation. (A) Possible binding site between Hsa_circ_0081065 and HIF-1 α was predicted by using CATRAPID; (B) RIP assay was used to detect the hsa_circ_0081065 enrichment enriched with HIF-1α antibody; (C) RNA EMSA assay was used to detect the binding between hsa_circ_0081065 and HIF-1α protein treatment with hsa_circ_0081065 RNA probe or and HIF-1α protein; (D) Western blot was used to detect the expression of HIF-1α treatment with intermittent hypoxia and with hsa_circ_0081065 silence in IH HUVEC cells; (E) IF was used to detect the HIF-1αnuclear translocation treatment with intermittent hypoxia and overexpression of hsa_circ_0081065. **P < 0.01, ***P < 0.001; ****P < 0.0001.